Key Developments: BioScrip Inc (BIOS.O)

BIOS.O on Nasdaq

6.12USD
19 Dec 2014
Price Change (% chg)

$-0.04 (-0.57%)
Prev Close
$6.16
Open
$6.14
Day's High
$6.21
Day's Low
$5.98
Volume
1,639,991
Avg. Vol
1,020,130
52-wk High
$9.05
52-wk Low
$5.44

Search Stocks

Latest Key Developments (Source: Significant Developments)

BioScrip Inc sees FY 2014 revenue guidance at high end of prior range
Wednesday, 5 Nov 2014 04:35pm EST 

BioScrip Inc:Says that revenue for FY 2014 is forecasted to be at high end of the company's guidance range of $940.0 million to $980.0 million.  Full Article

BioScrip, Inc announces auditor change - Form 8-K
Monday, 8 Sep 2014 05:00pm EDT 

BioScrip, Inc:Says on Sept. 2, 2014, it was notified by Ernst & Young LLP that it is resigning as the company‚Äôs independent public accounting firm effective after the company files its Form 10-Q for its fiscal quarter ending Sept. 30.Effective on Sept. 8, 2014, it approved the appointment of KPMG LLP to serve as the independent registered public accounting firm.  Full Article

BioScrip Inc sees FY 2014 revenue guidance at high end of prior range; reaffirms FY 2014 EBITDA guidance
Wednesday, 6 Aug 2014 04:30pm EDT 

BioScrip Inc:Projects that its FY 2014 revenue will be at high end of its guidance range of $940.0 mln to $980.0 mln and that its FY 2014 adjusted EBITDA will be in range of $55.0 mln to $60.0 mln.FY 2014 revenue of $966.2 mln - Thomson Reuters I/B/E/S.  Full Article

BioScrip Inc gives FY 2014 guidance above analysts' estimates
Thursday, 8 May 2014 10:55pm EDT 

BioScrip Inc:Sees FY 2014 revenue to be in a range of $940.0 million to $980.0 million.Sees FY 2014 Adjusted EBITDA will be in a range of $55.0 million to $60.0 million.FY 2014 revenue estimates of $713 mln -Thomson Reuters I/B/E/S.FY 2014 adjusted EBITDA estimates of $54 - Thomson Reuters I/B/E/S.  Full Article

LHC Group Inc completes acquisition of Deaconess HomeCare
Tuesday, 1 Apr 2014 07:00am EDT 

LHC Group Inc:Completes the transaction with BioScrip, Inc.To purchase two of BioScrip's operating subsidiaries, doing business as Deaconess HomeCare and Elk Valley Health Services, for $59.5 mln.Jones Walker LLP acted as LHC Group's legal advisor in connection with the transaction.  Full Article

BioScrip Inc to Sell Home Health Services Business to LHC Group, Inc
Monday, 3 Feb 2014 07:15am EST 

BioScrip Inc:Enters into a definitive agreement to sell its Home Health business, known as Deaconess HomeCare, to LHC Group, Inc.Says consideration for $60 mln in cash.Says net proceeds from the sale will be used to pay down debt.Says Cain Brothers & Co., LLC acted as BioScrip's financial advisor in connection with the transaction and Polsinelli PC acted as BioScrip's legal advisor.  Full Article

Saxena White P.A. Files Securities Fraud Class Action Against BioScrip, Inc
Monday, 18 Nov 2013 11:03am EST 

Saxena White P.A. announced that it has filed a securities fraud class action lawsuit in the United States District Court for the Southern District of New York against BioScrip, Inc. (BioScrip or the Company) and certain of the Company's executive officers and/or directors and underwriters. The class action is filed on behalf of investors who purchased or otherwise acquired BioScrip's common stock between August 8, 2011 and September 23, 2013, inclusive (the "Class Period"). The complaint brings forth claims for violations of the Securities Exchange Act of 1934. In addition, the class action complaint is also filed on behalf of investors who purchased BioScrip's common stock pursuant or traceable to the Company's Registration Statement and Prospectus ("Offering Documents") issued in connection with BioScrip's secondary public offerings during the Class Period. The complaint brings forth claims for violations of the Securities Act of 1933.  Full Article

BioScrip Inc Reaffirms FY 2013 Revenue Guidance; Lowers FY 2013 EBITDA Guidance
Wednesday, 6 Nov 2013 05:00pm EST 

BioScrip Inc announced that for fiscal 2013, it expects revenue to be in the range of $830.0 million to $850.0 million and believes its Adjusted EBITDA to be in the range of $50.0 million to $52.0 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $839 million and EBITDA of $55.0 million for fiscal 2013.  Full Article

Pomerantz Grossman Hufford Dahlstrom & Gross LLP Files Class Action Against BioScrip, Inc And Certain Officers
Friday, 25 Oct 2013 03:53pm EDT 

Pomerantz Grossman Hufford Dahlstrom & Gross LLP announced that it has filed a class action lawsuit against BioScrip, Inc. ("BioScrip" or the "Company") (NASDAQ: BIOS) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and docketed under 13-cv-6922, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of BioScrip between August 8, 2011 and September 20, 2013 both dates inclusive (the "Class Period"). This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.  Full Article

Morgan & Morgan Files Class Action Lawsuit Against BioScrip Inc
Monday, 7 Oct 2013 07:00pm EDT 

Morgan & Morgan announced that a class action has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired securities of BioScrip Inc common stock during the period between August 8, 2011 and September 20, 2013 (the Class Period). The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company improperly distributed the product Exjade through its specialty pharmacy operations; (2) the Company was in violation of certain federal and state laws and regulations; and (3) as a result of the foregoing, the Company's statements were materially false and misleading at all relevant times.  Full Article

BRIEF-UK retailer New Look sells French unit Mim to Asian group

* UK retailer New Look sells french unit Mim to Main Asia (HK) Limited

Search Stocks